NEW HAVEN, Conn. - eTradeWire -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.H) (the "Company" or "Bioasis") a biopharmaceutical company with a differentiated, proprietary platform (designated "xB3 ™") for delivering therapeutics across the blood-brain barrier ("BBB") and the treatment of central nervous system ("CNS") disorders in areas of high unmet medical need announced today that all of the members of its board of directors have resigned. Since the Company announced the suspension of operations in June 2023, it has continued to pursue a variety of potential strategic alternatives including the sale of some or all of its assets, mergers and reverse takeover transactions. These efforts have not yielded any actionable transactions.

More on eTradeWire News

• America Is Being Ripped Off: It's Time To Take Action Against Fraud & Foreign Exploitation
• USMC MOS Decals: Honoring Marine Corps Excellence
• Beverly Peyton has been endorsed for Bartow County Georgia GOP Chair by Veterans for America First
• Urbanate: Bridging the Equity Gap for Real Estate Developers with Global Investment Opportunities
• CSArts-SGV Popular Music Conservatory Hosts Benefit Concert for Fire Relief

The Company has exhausted its cash resources, remains in default of its obligations to its secured lenders and its shares continue to be subject to a cease trade order issued by the British Columbia Securities Commission due to the Company's failure to file financial statements, MD&A and related certifications starting in 2023.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.